Preclinical Studies Of Group A Streptococcal Vaccine Candidates
Funder
National Health and Medical Research Council
Funding Amount
$532,492.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Development Of Improved Vaccine Strategies For Measles Using Plant-derived Edible Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$331,980.00
Summary
Measles is a highly contagious viral disease that is contracted via the respiratory tract. Severe infection may lead to complications such as otitis media, pneumonia, encephalitis. Despite our current vaccination strategy outbreaks still occur in Australia and measles is a major problem in developing countries. In developing nations the case fatality rate of measles is several hundred times that of developed nations. Over 800,000 children still die each year due to measles. Problems with the cur ....Measles is a highly contagious viral disease that is contracted via the respiratory tract. Severe infection may lead to complications such as otitis media, pneumonia, encephalitis. Despite our current vaccination strategy outbreaks still occur in Australia and measles is a major problem in developing countries. In developing nations the case fatality rate of measles is several hundred times that of developed nations. Over 800,000 children still die each year due to measles. Problems with the current vaccination strategy are: a) doesn't work in children less than 1 year of age, b) must be kept cold c) must be given by injection. We believe that a plant derived edible vaccine for measles will address the limitations of currently available vaccine i.e. we can give it children under the age of 1 year, it can be eaten and doesn't have to be kept cold.Read moreRead less
Characterisation Of Rotavirus Vaccine Escape - Potential For Significant Impact On Vaccination Program
Funder
National Health and Medical Research Council
Funding Amount
$531,689.00
Summary
The introduction of rotavirus vaccines have had enormous impact on improving the health of children worldwide. However, the emergence of vaccine escape strains has the potential to significantly reduce the vaccine effectiveness. This study proposes to characterise strains able to escape vaccine protection.
Advanced Population-based Methods To Evaluate And Inform Immunisation Policy And Practice
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Despite the overall success of immunisation programs, preventable infections continue to occur, with Aboriginal children suffering the most. I will study the health and vaccination records for 1.95 million children (98,000 Aboriginal) in New South Wales and Western Australia to see who is most at risk of vaccine preventable infections and why. The findings will aid development of strategies to target high-risk children and to optimise the benefits obtained from Australia’s immunisation program.
Enabling Technologies For Design And Delivery Of Novel Vaccines Against Infectious Diseases And Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
This grant will support research necessary to develop the next generation of vaccines. These will combat diseases caused by bacteria and viruses and can also be used to fight cancer. The broad range of application is made possible through the incorporation of simple molecular features that activate the immune system. The intellectual property that has been developed is protected by a patent portfolio some patents of which are already licenced to the pharmaceutical industry.
Applying Active Hospital-based Case Ascertainment To Assess Vaccine Effectiveness And Safety
Funder
National Health and Medical Research Council
Funding Amount
$258,741.00
Summary
Australia makes a considerable investment in vaccination, and the public are entitled to expect that vaccines are both safe and effective. The growing complexity of the vaccine schedule requires the development of new and flexible systems to monitor vaccine performance. This project aims to do this using surveillance nurses embedded in children's hospitals to actively find cases of diseases which are potentially vaccine-preventable as well as those which might have occurred as a side effect of v ....Australia makes a considerable investment in vaccination, and the public are entitled to expect that vaccines are both safe and effective. The growing complexity of the vaccine schedule requires the development of new and flexible systems to monitor vaccine performance. This project aims to do this using surveillance nurses embedded in children's hospitals to actively find cases of diseases which are potentially vaccine-preventable as well as those which might have occurred as a side effect of vaccination.Read moreRead less
Development Of A Self-adjuvanting Mucosal Vaccine Candidate Against Group A Streptococcus Using Lipid Core Technology
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Novel developments in drug/vaccine delivery are clearly to have enormous economic and social impacts. My research aim is to rationally design and develop vaccines against relevant diseases. By understanding the mechanism of protection against diseases, development of novel vaccines for the treatment of many diseases can be achieved. This would contribute enormously to the betterment of public health.
Population-based Data Linkage And Modelling Studies To Evaluate And Inform Australia’s Immunisation Program
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
Despite the overall success of immunisation programs, outbreaks of preventable diseases continue and Indigenous children still suffer a higher burden of illness. We will study a cohort of infants in New South Wales and data about their illnesses and vaccinations to provide accurate measures program performance. The findings will aid development of strategies to target high risk children, and more realistic models about future outcomes, so that the benefits of immunisation are optimised.
Assessing Vaccine Effectiveness Of Publicly Funded Vaccination Programs In Queensland
Funder
National Health and Medical Research Council
Funding Amount
$99,883.00
Summary
I will measure how well three vaccines on the national immunisation schedule prevent disease in Queensland. Pertussis (whooping cough), rotavirus, and varicella (chicken-pox) vaccines will be assessed using routinely collected health data, such as disease notifications and hospitalisations, and vaccination data. The findings of this research will contribute to evaluating the effectiveness of these publicly funded vaccination programs and will provide an evidence base for future decision-making.
Protecting Australia From Future Swine Flu Pandemics-Functional And Structural Studies Of The H1N1 Swine Influenza A Surface Glycoprotein Hemagglutinin
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
The severity of the present and future pandemic strains of the swine flu will depend on the ability to contain and combat infection via pre-emptive development of appropriate vaccines and drugs. To this end, my study of the surface glycoprotein hemagglutinin, will help predict and prevent future swine influenza pandemics by identifying potentially pandemic strains to be targeted for early vaccine development.